JP2007523181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523181A5 JP2007523181A5 JP2006554235A JP2006554235A JP2007523181A5 JP 2007523181 A5 JP2007523181 A5 JP 2007523181A5 JP 2006554235 A JP2006554235 A JP 2006554235A JP 2006554235 A JP2006554235 A JP 2006554235A JP 2007523181 A5 JP2007523181 A5 JP 2007523181A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- chlorophenyl
- methyl
- triazol
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 86
- 150000001875 compounds Chemical class 0.000 claims 34
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 9
- -1 C 0-6 alkyl cyano Chemical group 0.000 claims 7
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 6
- 125000002877 alkyl aryl group Chemical group 0.000 claims 6
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims 5
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- COEDKNREIYXLSI-UHFFFAOYSA-N 3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)morpholine Chemical compound CN1C(N2C(COCC2)C=2ON=C(N=2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=NC=C1 COEDKNREIYXLSI-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- LJLCAWRLUYHWPG-GOSISDBHSA-N (2r)-2-[2-(3-chlorophenyl)tetrazol-5-yl]-1-[5-[4-(difluoromethoxy)phenyl]-4-methyl-1,2,4-triazol-3-yl]piperidine Chemical compound CN1C(N2[C@H](CCCC2)C2=NN(N=N2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=C(OC(F)F)C=C1 LJLCAWRLUYHWPG-GOSISDBHSA-N 0.000 claims 1
- LJLCAWRLUYHWPG-SFHVURJKSA-N (2s)-2-[2-(3-chlorophenyl)tetrazol-5-yl]-1-[5-[4-(difluoromethoxy)phenyl]-4-methyl-1,2,4-triazol-3-yl]piperidine Chemical compound CN1C(N2[C@@H](CCCC2)C2=NN(N=N2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=C(OC(F)F)C=C1 LJLCAWRLUYHWPG-SFHVURJKSA-N 0.000 claims 1
- OZTRBGCBUYSHIH-UHFFFAOYSA-N 1-[4-[5-[2-[2-(3-chlorophenyl)tetrazol-5-yl]piperidin-1-yl]-4-methyl-1,2,4-triazol-3-yl]phenyl]-n,n-dimethylmethanamine Chemical compound C1=CC(CN(C)C)=CC=C1C(N1C)=NN=C1N1C(C2=NN(N=N2)C=2C=C(Cl)C=CC=2)CCCC1 OZTRBGCBUYSHIH-UHFFFAOYSA-N 0.000 claims 1
- OYWMSINJPNNQCM-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)tetrazol-5-yl]-1-[5-(4-methoxyphenyl)-4-methyl-1,2,4-triazol-3-yl]piperidine Chemical compound C1=CC(OC)=CC=C1C(N1C)=NN=C1N1C(C2=NN(N=N2)C=2C=C(Cl)C=CC=2)CCCC1 OYWMSINJPNNQCM-UHFFFAOYSA-N 0.000 claims 1
- LJLCAWRLUYHWPG-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)tetrazol-5-yl]-1-[5-[4-(difluoromethoxy)phenyl]-4-methyl-1,2,4-triazol-3-yl]piperidine Chemical compound CN1C(N2C(CCCC2)C2=NN(N=N2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=C(OC(F)F)C=C1 LJLCAWRLUYHWPG-UHFFFAOYSA-N 0.000 claims 1
- FHZOCFQDSRGDSV-UHFFFAOYSA-N 2-[4-[5-[2-[2-(3-chlorophenyl)tetrazol-5-yl]piperidin-1-yl]-4-methyl-1,2,4-triazol-3-yl]phenoxy]-n,n-dimethylethanamine Chemical compound C1=CC(OCCN(C)C)=CC=C1C(N1C)=NN=C1N1C(C2=NN(N=N2)C=2C=C(Cl)C=CC=2)CCCC1 FHZOCFQDSRGDSV-UHFFFAOYSA-N 0.000 claims 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 1
- HWULKQPTXYXSFV-UHFFFAOYSA-N 3-(3-chlorophenyl)-5-[1-[5-[4-(difluoromethoxy)phenyl]-4-methyl-1,2,4-triazol-3-yl]-4-methylpiperazin-2-yl]-1,2,4-oxadiazole Chemical compound C1N(C)CCN(C=2N(C(C=3C=CC(OC(F)F)=CC=3)=NN=2)C)C1C(ON=1)=NC=1C1=CC=CC(Cl)=C1 HWULKQPTXYXSFV-UHFFFAOYSA-N 0.000 claims 1
- STZIBMDUCHDHGE-UHFFFAOYSA-N 3-(3-chlorophenyl)-5-[1-[5-[4-(difluoromethoxy)phenyl]-4-methyl-1,2,4-triazol-3-yl]piperazin-2-yl]-1,2,4-oxadiazole Chemical compound CN1C(N2C(CNCC2)C=2ON=C(N=2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=C(OC(F)F)C=C1 STZIBMDUCHDHGE-UHFFFAOYSA-N 0.000 claims 1
- ZEBYNCUDWGJZBT-UHFFFAOYSA-N 3-[2-(3-chlorophenyl)tetrazol-5-yl]-4-(4-methyl-5-pyridin-3-yl-1,2,4-triazol-3-yl)morpholine Chemical compound CN1C(N2C(COCC2)C2=NN(N=N2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=CN=C1 ZEBYNCUDWGJZBT-UHFFFAOYSA-N 0.000 claims 1
- QLPBAJLVPRVQPK-UHFFFAOYSA-N 3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-(4-methyl-5-pyridin-2-yl-1,2,4-triazol-3-yl)morpholine Chemical compound CN1C(N2C(COCC2)C=2ON=C(N=2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=CC=N1 QLPBAJLVPRVQPK-UHFFFAOYSA-N 0.000 claims 1
- VKFARRGJLNLUNZ-UHFFFAOYSA-N 3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-[4-methyl-5-(2-methylpyridin-4-yl)-1,2,4-triazol-3-yl]morpholine Chemical compound C1=NC(C)=CC(C=2N(C(N3C(COCC3)C=3ON=C(N=3)C=3C=C(Cl)C=CC=3)=NN=2)C)=C1 VKFARRGJLNLUNZ-UHFFFAOYSA-N 0.000 claims 1
- BMBOVYYGRBSUDZ-UHFFFAOYSA-N 3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-[5-(2-methoxypyridin-4-yl)-4-methyl-1,2,4-triazol-3-yl]morpholine Chemical compound C1=NC(OC)=CC(C=2N(C(N3C(COCC3)C=3ON=C(N=3)C=3C=C(Cl)C=CC=3)=NN=2)C)=C1 BMBOVYYGRBSUDZ-UHFFFAOYSA-N 0.000 claims 1
- HGWNIIBVZCOXDW-UHFFFAOYSA-N 3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-[5-(5-fluoropyridin-3-yl)-4-methyl-1,2,4-triazol-3-yl]morpholine Chemical compound CN1C(N2C(COCC2)C=2ON=C(N=2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CN=CC(F)=C1 HGWNIIBVZCOXDW-UHFFFAOYSA-N 0.000 claims 1
- JVWPSADWKHCVCF-UHFFFAOYSA-N 3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-[5-[4-(difluoromethoxy)phenyl]-4-methyl-1,2,4-triazol-3-yl]morpholine Chemical compound CN1C(N2C(COCC2)C=2ON=C(N=2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=C(OC(F)F)C=C1 JVWPSADWKHCVCF-UHFFFAOYSA-N 0.000 claims 1
- SBMBXEIMVPVFGO-UHFFFAOYSA-N 3-[3-(3-iodophenyl)-1,2,4-oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)morpholine Chemical compound CN1C(N2C(COCC2)C=2ON=C(N=2)C=2C=C(I)C=CC=2)=NN=C1C1=CC=NC=C1 SBMBXEIMVPVFGO-UHFFFAOYSA-N 0.000 claims 1
- JGQPBUFPCJCRRJ-UHFFFAOYSA-N 3-[5-(3-chlorophenyl)-1,2-oxazol-3-yl]-4-(4-cyclopropyl-5-pyridin-3-yl-1,2,4-triazol-3-yl)morpholine Chemical compound ClC1=CC=CC(C=2ON=C(C=2)C2N(CCOC2)C=2N(C(C=3C=NC=CC=3)=NN=2)C2CC2)=C1 JGQPBUFPCJCRRJ-UHFFFAOYSA-N 0.000 claims 1
- LCBVGMNYUDKYGU-UHFFFAOYSA-N 3-[5-(3-chlorophenyl)-1,2-oxazol-3-yl]-4-(4-cyclopropyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)morpholine Chemical compound ClC1=CC=CC(C=2ON=C(C=2)C2N(CCOC2)C=2N(C(C=3C=CN=CC=3)=NN=2)C2CC2)=C1 LCBVGMNYUDKYGU-UHFFFAOYSA-N 0.000 claims 1
- UDMZAJMOBBCCHF-UHFFFAOYSA-N 3-[5-(3-chlorophenyl)-1,2-oxazol-3-yl]-4-(4-methyl-5-pyridin-3-yl-1,2,4-triazol-3-yl)morpholine Chemical compound CN1C(N2C(COCC2)C2=NOC(=C2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=CN=C1 UDMZAJMOBBCCHF-UHFFFAOYSA-N 0.000 claims 1
- KSEKNSKYZOWWBP-UHFFFAOYSA-N 3-[5-(3-chlorophenyl)-1,2-oxazol-3-yl]-4-(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)morpholine Chemical compound CN1C(N2C(COCC2)C2=NOC(=C2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=NC=C1 KSEKNSKYZOWWBP-UHFFFAOYSA-N 0.000 claims 1
- ODEQTMFHSAJMGD-UHFFFAOYSA-N 3-[5-(3-chlorophenyl)-1,2-oxazol-3-yl]-4-[5-(6-methoxypyridin-3-yl)-4-methyl-1,2,4-triazol-3-yl]morpholine Chemical compound C1=NC(OC)=CC=C1C(N1C)=NN=C1N1C(C2=NOC(=C2)C=2C=C(Cl)C=CC=2)COCC1 ODEQTMFHSAJMGD-UHFFFAOYSA-N 0.000 claims 1
- GXQGOISQSIBNBV-UHFFFAOYSA-N 3-[5-(3-chlorophenyl)-1,2-oxazol-3-yl]-4-[5-[4-(difluoromethoxy)phenyl]-4-methyl-1,2,4-triazol-3-yl]morpholine Chemical compound CN1C(N2C(COCC2)C2=NOC(=C2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=C(OC(F)F)C=C1 GXQGOISQSIBNBV-UHFFFAOYSA-N 0.000 claims 1
- FFDPZXPWIUFSNL-UHFFFAOYSA-N 4-[5-(5-fluoropyridin-3-yl)-4-methyl-1,2,4-triazol-3-yl]-3-[3-(3-iodophenyl)-1,2,4-oxadiazol-5-yl]morpholine Chemical compound CN1C(N2C(COCC2)C=2ON=C(N=2)C=2C=C(I)C=CC=2)=NN=C1C1=CN=CC(F)=C1 FFDPZXPWIUFSNL-UHFFFAOYSA-N 0.000 claims 1
- RVASUAXSNQNQBP-QGZVFWFLSA-N 4-[5-[(2r)-2-[2-(3-chlorophenyl)tetrazol-5-yl]piperidin-1-yl]-4-methyl-1,2,4-triazol-3-yl]pyridine Chemical compound CN1C(N2[C@H](CCCC2)C2=NN(N=N2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=NC=C1 RVASUAXSNQNQBP-QGZVFWFLSA-N 0.000 claims 1
- RVASUAXSNQNQBP-KRWDZBQOSA-N 4-[5-[(2s)-2-[2-(3-chlorophenyl)tetrazol-5-yl]piperidin-1-yl]-4-methyl-1,2,4-triazol-3-yl]pyridine Chemical compound CN1C(N2[C@@H](CCCC2)C2=NN(N=N2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=NC=C1 RVASUAXSNQNQBP-KRWDZBQOSA-N 0.000 claims 1
- CGQKYGXPSQYVBT-UHFFFAOYSA-N 4-[5-[2-[2-(3-chlorophenyl)tetrazol-5-yl]piperidin-1-yl]-4-methyl-1,2,4-triazol-3-yl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C(N1C)=NN=C1N1C(C2=NN(N=N2)C=2C=C(Cl)C=CC=2)CCCC1 CGQKYGXPSQYVBT-UHFFFAOYSA-N 0.000 claims 1
- RVASUAXSNQNQBP-UHFFFAOYSA-N 4-[5-[2-[2-(3-chlorophenyl)tetrazol-5-yl]piperidin-1-yl]-4-methyl-1,2,4-triazol-3-yl]pyridine Chemical compound CN1C(N2C(CCCC2)C2=NN(N=N2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=NC=C1 RVASUAXSNQNQBP-UHFFFAOYSA-N 0.000 claims 1
- WMQKIUPAAGKKPN-UHFFFAOYSA-N 4-[5-[5-[2-[5-(3-chlorophenyl)-1,2-oxazol-3-yl]pyrrolidin-1-yl]-4-cyclopropyl-1,2,4-triazol-3-yl]pyridin-2-yl]morpholine Chemical compound ClC1=CC=CC(C=2ON=C(C=2)C2N(CCC2)C=2N(C(C=3C=NC(=CC=3)N3CCOCC3)=NN=2)C2CC2)=C1 WMQKIUPAAGKKPN-UHFFFAOYSA-N 0.000 claims 1
- LBFBVMKFEKJSPD-UHFFFAOYSA-N 4-[5-[5-[2-[5-(3-chlorophenyl)-1,2-oxazol-3-yl]pyrrolidin-1-yl]-4-methyl-1,2,4-triazol-3-yl]pyridin-2-yl]morpholine Chemical compound CN1C(N2C(CCC2)C2=NOC(=C2)C=2C=C(Cl)C=CC=2)=NN=C1C(C=N1)=CC=C1N1CCOCC1 LBFBVMKFEKJSPD-UHFFFAOYSA-N 0.000 claims 1
- MCSONFKJRPIXCL-UHFFFAOYSA-N 5-(3-chlorophenyl)-3-[1-(4-cyclopropyl-5-pyridin-3-yl-1,2,4-triazol-3-yl)pyrrolidin-2-yl]-1,2-oxazole Chemical compound ClC1=CC=CC(C=2ON=C(C=2)C2N(CCC2)C=2N(C(C=3C=NC=CC=3)=NN=2)C2CC2)=C1 MCSONFKJRPIXCL-UHFFFAOYSA-N 0.000 claims 1
- PDFMASTVGWKOEJ-UHFFFAOYSA-N 5-(3-chlorophenyl)-3-[1-(4-methyl-5-pyridin-3-yl-1,2,4-triazol-3-yl)pyrrolidin-2-yl]-1,2-oxazole Chemical compound CN1C(N2C(CCC2)C2=NOC(=C2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=CN=C1 PDFMASTVGWKOEJ-UHFFFAOYSA-N 0.000 claims 1
- WPUHDOULWWBRQB-UHFFFAOYSA-N 5-(3-chlorophenyl)-3-[1-(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)piperidin-2-yl]-1,2-oxazole Chemical compound CN1C(N2C(CCCC2)C2=NOC(=C2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=NC=C1 WPUHDOULWWBRQB-UHFFFAOYSA-N 0.000 claims 1
- WTRVDJVFAYUCOM-UHFFFAOYSA-N 5-(3-chlorophenyl)-3-[1-(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)pyrrolidin-2-yl]-1,2-oxazole Chemical compound CN1C(N2C(CCC2)C2=NOC(=C2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=NC=C1 WTRVDJVFAYUCOM-UHFFFAOYSA-N 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- RJTPNVILMCXEKY-UHFFFAOYSA-N tert-butyl 3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)piperazine-1-carboxylate Chemical compound CN1C(N2C(CN(CC2)C(=O)OC(C)(C)C)C=2ON=C(N=2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=NC=C1 RJTPNVILMCXEKY-UHFFFAOYSA-N 0.000 claims 1
- QIIJLXWOGFWAKA-UHFFFAOYSA-N tert-butyl 3-[3-(3-chlorophenyl)-1,2,4-oxadiazol-5-yl]-4-[5-[4-(difluoromethoxy)phenyl]-4-methyl-1,2,4-triazol-3-yl]piperazine-1-carboxylate Chemical compound CN1C(N2C(CN(CC2)C(=O)OC(C)(C)C)C=2ON=C(N=2)C=2C=C(Cl)C=CC=2)=NN=C1C1=CC=C(OC(F)F)C=C1 QIIJLXWOGFWAKA-UHFFFAOYSA-N 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54529204P | 2004-02-18 | 2004-02-18 | |
| PCT/US2005/005216 WO2005080386A1 (en) | 2004-02-18 | 2005-02-17 | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007523181A JP2007523181A (ja) | 2007-08-16 |
| JP2007523181A5 true JP2007523181A5 (https=) | 2008-04-10 |
Family
ID=34886130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006554235A Pending JP2007523181A (ja) | 2004-02-18 | 2005-02-17 | ポリヘテロ環式化合物、および、代謝型グルタミン酸受容体アンタゴニストとしてのそれらの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20070185100A1 (https=) |
| EP (1) | EP1716143A1 (https=) |
| JP (1) | JP2007523181A (https=) |
| KR (1) | KR20070052693A (https=) |
| CN (1) | CN1918154A (https=) |
| AR (1) | AR047966A1 (https=) |
| AU (1) | AU2005214378A1 (https=) |
| BR (1) | BRPI0507481A (https=) |
| CA (1) | CA2555272A1 (https=) |
| IL (1) | IL177058A0 (https=) |
| MX (1) | MXPA06009023A (https=) |
| NO (1) | NO20063469L (https=) |
| NZ (1) | NZ548693A (https=) |
| RU (1) | RU2381226C2 (https=) |
| SG (1) | SG149900A1 (https=) |
| TW (1) | TW200538179A (https=) |
| UA (1) | UA82434C2 (https=) |
| UY (1) | UY28764A1 (https=) |
| WO (1) | WO2005080386A1 (https=) |
| ZA (1) | ZA200606314B (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070185100A1 (en) * | 2004-02-18 | 2007-08-09 | Astrazeneca Ab | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| WO2006048771A1 (en) * | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| CN102633730A (zh) * | 2004-12-03 | 2012-08-15 | 先灵公司 | 作为cb1拮抗剂的取代哌嗪 |
| JPWO2006080533A1 (ja) * | 2005-01-31 | 2008-06-19 | 持田製薬株式会社 | ３−アミノ−１，２，４−トリアゾール誘導体 |
| GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| EP1893606A2 (en) * | 2005-05-18 | 2008-03-05 | Addex Pharma SA | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| UY29796A1 (es) | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
| HUP0500921A2 (en) * | 2005-10-05 | 2007-07-30 | Richter Gedeon Nyrt | Tetrazole derivatives, process for their preparation and their use |
| TW200811137A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators II |
| TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
| TW200811156A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators IV |
| TW200808777A (en) * | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGLUR5 modulators III |
| US7943622B2 (en) | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
| CA2692268A1 (en) * | 2007-06-28 | 2009-01-08 | Intervet International B.V. | Substituted piperazines as cb1 antagonists |
| US20100249144A1 (en) * | 2007-06-28 | 2010-09-30 | Demong Duane Eugene | Substituted piperazines as cb1 antagonists |
| BRPI0818448A2 (pt) | 2007-10-19 | 2015-05-12 | Astrazeneca Ab | Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou prevenção de um distúrbio madiano pelo receptor mglur5. |
| WO2009054791A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mglur5 |
| TW200922586A (en) * | 2007-10-26 | 2009-06-01 | Astrazeneca Ab | Thiophene 1,2,4-triazole derivatives as modulators of mGluR5 |
| WO2009054792A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Aminopyridine derivatives as modulators of mglur5 |
| WO2009054787A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole carboxylic acid derivatives as modulators of mglur5 |
| WO2009054786A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5 |
| WO2009054789A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,3-triazole pyrrolidine derivatives as modulators of mglur5 |
| US8546576B2 (en) * | 2008-06-06 | 2013-10-01 | Sk Biopharmaceuticals Co., Ltd. | 3 or 4-substituted piperidine compounds |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| WO2010114971A1 (en) * | 2009-04-03 | 2010-10-07 | Sepracor Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| EP2421370A4 (en) * | 2009-04-23 | 2012-12-12 | Merck Sharp & Dohme | 2-alkyl-piperidine-mGluR5 receptor MODULATORS |
| AR080056A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de ciclohexil-amida como antagonistas de los receptores de crf |
| JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体 |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| WO2014022752A1 (en) | 2012-08-03 | 2014-02-06 | Amgen Inc. | Macrocycles as pim inhibitors |
| CA2912735A1 (en) * | 2013-06-11 | 2014-12-18 | F. Hoffmann-La Roche Ag | Novel tetrazolone derivatives |
| MY202326A (en) * | 2017-09-14 | 2024-04-24 | Daiichi Sankyo Co Ltd | Compound having cyclic structure |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL83275A (en) * | 1986-09-08 | 1994-02-27 | Novo Nordisk As | Substituted 1, 2, 4- oxadiazolyl piperidine compounds, their preparation and pharmaceutical compositions containing them |
| KR100875222B1 (ko) * | 1999-08-19 | 2008-12-19 | 아스트라제네카 아베 | 헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도 |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| AU2002227020A1 (en) * | 2001-01-05 | 2002-07-16 | Eli Lilly And Company | Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists |
| JP4303109B2 (ja) * | 2001-10-04 | 2009-07-29 | メルク エンド カムパニー インコーポレーテッド | 代謝共役型グルタミン酸受容体−５のヘテロアリール置換テトラゾール調節剤 |
| EP1485093B1 (en) * | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| SE0201943D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New use |
| US7074809B2 (en) * | 2002-08-09 | 2006-07-11 | Astrazeneca Ab | Compounds |
| CA2542522A1 (en) * | 2003-10-17 | 2005-05-06 | Astrazeneca Ab | 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
| GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| US20070185100A1 (en) * | 2004-02-18 | 2007-08-09 | Astrazeneca Ab | Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
| TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
-
2005
- 2005-02-17 US US10/588,754 patent/US20070185100A1/en not_active Abandoned
- 2005-02-17 KR KR1020067015825A patent/KR20070052693A/ko not_active Ceased
- 2005-02-17 UA UAA200608216A patent/UA82434C2/uk unknown
- 2005-02-17 AU AU2005214378A patent/AU2005214378A1/en not_active Abandoned
- 2005-02-17 SG SG200900931-7A patent/SG149900A1/en unknown
- 2005-02-17 TW TW094104643A patent/TW200538179A/zh unknown
- 2005-02-17 NZ NZ548693A patent/NZ548693A/en unknown
- 2005-02-17 CN CNA2005800043398A patent/CN1918154A/zh active Pending
- 2005-02-17 CA CA002555272A patent/CA2555272A1/en not_active Abandoned
- 2005-02-17 JP JP2006554235A patent/JP2007523181A/ja active Pending
- 2005-02-17 MX MXPA06009023A patent/MXPA06009023A/es active IP Right Grant
- 2005-02-17 WO PCT/US2005/005216 patent/WO2005080386A1/en not_active Ceased
- 2005-02-17 BR BRPI0507481-9A patent/BRPI0507481A/pt not_active IP Right Cessation
- 2005-02-17 RU RU2006127572/04A patent/RU2381226C2/ru not_active IP Right Cessation
- 2005-02-17 EP EP05713792A patent/EP1716143A1/en not_active Withdrawn
- 2005-02-18 AR ARP050100612A patent/AR047966A1/es unknown
- 2005-02-18 UY UY28764A patent/UY28764A1/es unknown
- 2005-02-18 US US11/060,561 patent/US20060025414A1/en not_active Abandoned
-
2006
- 2006-07-25 IL IL177058A patent/IL177058A0/en unknown
- 2006-07-28 NO NO20063469A patent/NO20063469L/no not_active Application Discontinuation
- 2006-07-28 ZA ZA200606314A patent/ZA200606314B/xx unknown